Literature DB >> 19104706

Quality of life in inflammatory bowel disease: psychometric evaluation of an IBDQ cross-culturally adapted version.

Ramiro Verissimo1.   

Abstract

BACKGROUND & AIMS: The health related quality of life (HR-QoL) construct was introduced as a requirement to assess the subjective health status. It is a multifaceted construct that has contributed to a better understanding of the patients' adaptation to his condition. The Inflammatory Bowel Disease Questionnaire (IBDQ), a widely used instrument to assess QoL among IBD patients, has already shown its validity and reliability. Our aim was to obtain an easier revised version of the (IBDQ-R) and to investigate its cross-cultural psychometric properties.
METHOD: Carried out in a sample of outpatients recruited in a specialized University Clinic (n=76), this study began with the translation and linguistic validation of a self-report 32-item version of the questionnaire with a 7-point Likert type answering system. We assessed thereafter its reliability through internal consistencies and also looked into its discriminatory power. We also investigated its convergent validity with other health status - clinical assessment, SCDAI and CDAI-m - and well-being measures.
RESULTS: With a Cronbach's alpha = 0.92 for the global scale and a mean 0.82 for the subscales, internal consistencies proved adequate. On the other hand, discriminatory power was also significant according to the model. Moreover, the expected correlations between IBDQ and the clinical assessment, SCDAI, CDAI-m and perception of well-being support evidence of IBDQ-R's convergent validity.
CONCLUSION: This IBDQ revised version is a highly promising instrument to easily, yet feasibly and comprehensively, assess the quality of life in inflammatory bowel disease; therefore its use in daily practice is worthy to be recommended.

Entities:  

Mesh:

Year:  2008        PMID: 19104706

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  7 in total

1.  Crohn's disease: Adalimumab improves quality of life.

Authors:  Konstantinos A Papadakis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-04       Impact factor: 46.802

2.  Estimation of quality of life in Cypriot patients with inflammatory bowel disease.

Authors:  Maria Tsoukka; Eleni Jelastopulu; Giagkos Lavranos; George Charalambous
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

Review 3.  Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review.

Authors:  Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey
Journal:  Qual Life Res       Date:  2017-08-28       Impact factor: 4.147

Review 4.  Assessing patient reported outcome measures: A practical guide for gastroenterologists.

Authors:  Laith Alrubaiy; Hayley A Hutchings; John G Williams
Journal:  United European Gastroenterol J       Date:  2014-12       Impact factor: 4.623

5.  The specialized educational and psychological counseling in inflammatory bowel disease patients - a target or a challenge?

Authors:  Otilia Gavrilescu; Cristina Cijevschi Prelipcean; Mihaela Dranga; Camelia Soponaru; Catalina Mihai
Journal:  Turk J Gastroenterol       Date:  2020-11       Impact factor: 1.852

6.  Effects of soy milk consumption on gut microbiota, inflammatory markers, and disease severity in patients with ulcerative colitis: a study protocol for a randomized clinical trial.

Authors:  Omid Sadeghi; Alireza Milajerdi; Seyed Davar Siadat; Seyed Ali Keshavarz; Ali Reza Sima; Homayoon Vahedi; Peyman Adibi; Ahmad Esmaillzadeh
Journal:  Trials       Date:  2020-06-23       Impact factor: 2.279

7.  The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life and oxidant/anti-oxidant status.

Authors:  Sara Karimi; Sanam Tabataba-Vakili; Zahra Yari; Forough Alborzi; Mehdi Hedayati; Nasser Ebrahimi-Daryani; Azita Hekmatdoost
Journal:  Nutr J       Date:  2019-03-11       Impact factor: 3.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.